PH22649A - Crystal suspensions of insulin derivatives and process for their preparation - Google Patents

Crystal suspensions of insulin derivatives and process for their preparation

Info

Publication number
PH22649A
PH22649A PH31042A PH31042A PH22649A PH 22649 A PH22649 A PH 22649A PH 31042 A PH31042 A PH 31042A PH 31042 A PH31042 A PH 31042A PH 22649 A PH22649 A PH 22649A
Authority
PH
Philippines
Prior art keywords
isoelectric point
group
preparation
insulin derivatives
suspensions
Prior art date
Application number
PH31042A
Other languages
English (en)
Inventor
Grau Ulrich
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of PH22649A publication Critical patent/PH22649A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C07K14/622—Insulins at least 1 amino acid in D-form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Metallurgy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PH31042A 1983-07-29 1984-07-27 Crystal suspensions of insulin derivatives and process for their preparation PH22649A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19833327709 DE3327709A1 (de) 1983-07-29 1983-07-29 Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung

Publications (1)

Publication Number Publication Date
PH22649A true PH22649A (en) 1988-10-28

Family

ID=6205461

Family Applications (1)

Application Number Title Priority Date Filing Date
PH31042A PH22649A (en) 1983-07-29 1984-07-27 Crystal suspensions of insulin derivatives and process for their preparation

Country Status (20)

Country Link
US (1) US4959351A (hu)
EP (1) EP0133285B1 (hu)
JP (1) JPH0764876B2 (hu)
KR (1) KR910009344B1 (hu)
AT (1) ATE32729T1 (hu)
AU (1) AU567360B2 (hu)
CA (1) CA1246549A (hu)
DE (2) DE3327709A1 (hu)
DK (1) DK172241B1 (hu)
ES (1) ES534684A0 (hu)
FI (1) FI80277C (hu)
GR (1) GR82438B (hu)
HU (1) HU201096B (hu)
IE (1) IE57711B1 (hu)
IL (1) IL72512A (hu)
NO (1) NO167207C (hu)
NZ (1) NZ209041A (hu)
PH (1) PH22649A (hu)
PT (1) PT78980A (hu)
ZA (1) ZA845819B (hu)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK347086D0 (da) * 1986-07-21 1986-07-21 Novo Industri As Novel peptides
US4946828A (en) * 1985-03-12 1990-08-07 Novo Nordisk A/S Novel insulin peptides
DK119785D0 (da) * 1985-03-15 1985-03-15 Nordisk Gentofte Insulinpraeparat
DE3604868A1 (de) * 1986-02-15 1987-08-20 Behringwerke Ag Insulinderivate, verfahren zu ihrer herstellung und ihre verwendung
DE3837825A1 (de) * 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
DE3844211A1 (de) * 1988-12-29 1990-07-05 Hoechst Ag Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
DK134189D0 (da) * 1989-03-20 1989-03-20 Nordisk Gentofte Insulinforbindelser
AU9172991A (en) 1990-12-07 1992-07-08 Cnc Development, Inc. Catalytic chemical reactor
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
DE122006000017I1 (de) * 1993-06-21 2006-06-29 Novo Nordisk As ASP-B28-Insulinkristalle
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5547929A (en) * 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
US5597893A (en) * 1994-10-31 1997-01-28 Eli Lilly And Company Preparation of stable insulin analog crystals
AR002976A1 (es) * 1995-03-31 1998-05-27 Lilly Co Eli Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas
WO1997005166A1 (en) 1995-07-25 1997-02-13 Novartis Ag Transforming growth factor beta crystals
DK0821006T3 (da) * 1996-07-26 2004-08-16 Aventis Pharma Gmbh Insulinderivater med öget zinkbinding
ES2242270T3 (es) * 1997-02-07 2005-11-01 Novo Nordisk A/S Cristalizacion de proteinas.
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
JP2001521006A (ja) 1997-10-24 2001-11-06 イーライ・リリー・アンド・カンパニー 不溶性インシュリン組成物
US6531448B1 (en) * 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose
US6541606B2 (en) * 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
IL156618A0 (en) * 2000-12-28 2004-01-04 Altus Biologics Inc Crystals of whole antibodies and fragments thereof, methods for the preparation thereof and diagnostic kits utilizing the same
ATE439378T1 (de) * 2001-02-09 2009-08-15 Genentech Inc Verfahren zur identifizierung von indirekten igf- 1-agonisten
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
WO2003000014A2 (en) * 2001-06-21 2003-01-03 Altus Biologics, Inc. Spherical protein particles and methods of making and using them
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
PL373543A1 (pl) * 2005-03-10 2006-09-18 Instytut Biotechnologii i Antybiotyków Kompozycja farmaceutyczna zawierająca biosyntetyczny analog insuliny ludzkiej, oraz jej zastosowanie w terapii cukrzycy
WO2008065138A1 (en) * 2006-11-29 2008-06-05 Novo Nordisk A/S Novel insulin crystal and method for preparing the crystal
PL219335B1 (pl) * 2008-07-04 2015-04-30 Inst Biotechnologii I Antybiotyków Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna
KR101820024B1 (ko) 2008-10-17 2018-01-18 사노피-아벤티스 도이칠란트 게엠베하 인슐린과 ｇｌｐ－1 효능제의 병용물
HUE037735T2 (hu) 2009-11-13 2018-09-28 Sanofi Aventis Deutschland DesPro36exendin-4(1-39)-Lys6-NH2-t és metionint tartalmazó gyógyszerkészítmény
ES2534191T3 (es) 2009-11-13 2015-04-20 Sanofi-Aventis Deutschland Gmbh Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
BR112013004756B1 (pt) 2010-08-30 2020-04-28 Sanofi Aventis Deutschland uso de ave0010 para a fabricação de um medicamento para o tratamento da diabetes melito tipo 2
CN102219851B (zh) * 2011-05-09 2012-05-30 甘李药业有限公司 甘精胰岛素结晶的制备方法
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
RU2650616C2 (ru) 2011-08-29 2018-04-16 Санофи-Авентис Дойчланд Гмбх Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
WO2014161835A1 (en) * 2013-04-03 2014-10-09 Sanofi Modified blood glucose regulating proteins with altered pharmacological activity profile and preparation thereof
EP3077414B1 (en) * 2013-12-04 2020-06-17 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin
JP6970615B2 (ja) 2014-12-12 2021-11-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング インスリングラルギン／リキシセナチド固定比処方
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB729670A (en) * 1951-11-15 1955-05-11 Novo Terapeutisk Labor As Improved process for the production of insulin in crystalline form and crystalline insulin produced thereby
DK78069C (da) * 1952-06-23 1954-09-06 Novo Terapeutisk Labor As Fremgangsmåde til fremstilling af krystallinsk insulin.
US3719655A (en) * 1969-12-05 1973-03-06 Lilly Co Eli Process for the crystallization of the ammonium and alkali metal salts in insulin
DE2459515C3 (de) * 1974-12-17 1982-02-11 Hoechst Ag, 6000 Frankfurt Arzneimittelzubereitungen mit antidiabetischer Wirkung
DK319780A (da) * 1980-07-24 1982-01-25 Forenede Bryggerier As Fremgangsmaade til enzymatisk udskiftning af b-30 aminosyren i insuliner
NL8201650A (nl) * 1982-04-21 1983-11-16 Akzo Nv Semisynthetische bereiding van humane insuline.
DE3327928A1 (de) * 1983-08-03 1985-02-21 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von insulin-derivaten

Also Published As

Publication number Publication date
DK172241B1 (da) 1998-02-02
DE3327709A1 (de) 1985-02-07
IL72512A (en) 1989-08-15
US4959351A (en) 1990-09-25
FI80277C (fi) 1990-05-10
IE841947L (en) 1985-01-29
JPS6051118A (ja) 1985-03-22
PT78980A (de) 1984-08-01
ATE32729T1 (de) 1988-03-15
ES8601109A1 (es) 1985-10-16
DE3469535D1 (en) 1988-04-07
FI80277B (fi) 1990-01-31
DK368884D0 (da) 1984-07-27
HUT35001A (en) 1985-05-28
NO843048L (no) 1985-01-30
AU567360B2 (en) 1987-11-19
KR850000981A (ko) 1985-03-14
IL72512A0 (en) 1984-11-30
ZA845819B (en) 1985-03-27
NZ209041A (en) 1989-02-24
FI842981A (fi) 1985-01-30
EP0133285B1 (de) 1988-03-02
FI842981A0 (fi) 1984-07-26
HU201096B (en) 1990-09-28
EP0133285A1 (de) 1985-02-20
DK368884A (da) 1985-01-30
NO167207B (no) 1991-07-08
NO167207C (no) 1991-10-16
IE57711B1 (en) 1993-03-10
JPH0764876B2 (ja) 1995-07-12
KR910009344B1 (ko) 1991-11-12
AU3127284A (en) 1985-01-31
CA1246549A (en) 1988-12-13
GR82438B (hu) 1984-12-13
ES534684A0 (es) 1985-10-16

Similar Documents

Publication Publication Date Title
DE3469535D1 (en) Crystal suspensions of insulin derivatives, process for their preparation and their use
HUT52549A (en) Process for production of new derivatives of insuline and medical compositions containing them
HUT53150A (en) Process for producing new insulin derivatives and pharmaceutical compositions comprising same
DE3482387D1 (en) Polypeptide.
JPS55151555A (en) Proline derivatives and their production
JPS557255A (en) Thiazolidine derivative
ATE52782T1 (de) Ein-topfverfahren fuer herstellung von 7 betaamino- und 7 beta-acylamino-3-substituierte